EXAMPLE 1 preparation of anti-AlEcR-A protein monoclonal antibody
Firstly, construction of pCzn1-AlEcR-A recombinant expression plasmid
The gene AlEcR-A is connected into an expression vector pCzn1 through cloning sites Nde I and XbA I by A PAS (PCR-based Accurate Synthesis) method; the obtained recombinant plasmid pCzn1-AlEcR-A is transferred into A TOP10 clone strain; selecting positive clones for sequencing, comparing the sequencing result with an expected sequence, and intercepting part of the compared sequence as shown in figure 1; the sequencing result shows that the T4DNA is successfully connected with the expression vector pCzn1 subjected to double enzyme digestion and A T vector containing an AlEcR-A sequence, which indicates that the AlEcR-A is subcloned onto the pCzn1 vector and is named as pCzn1-AlEcR-A (figure 2); meanwhile, plasmid restriction identification (AlEcR-AD260/OD280:1.84) is carried out, and the restriction system is as follows:
the results of enzyme cleavage identification are shown in FIG. 2. The recombinant plasmid pCzn1-AlEcR-A with correct sequencing is transformed into an EscherichiA coli Arctic express strain: adding 1. mu.l of recombinant plasmid pCzn1-AlEcR-A into 100. mu.l of competent cells, and placing on ice for 20 min; thermally shocking at 42 deg.C for 90sec, and rapidly placing in ice for 5 min; adding 600 mul LB culture liquid; shaking at 37 deg.C and 220rpm for 1h, centrifuging, spreading on LB plate containing 50 μ g/ml Amp, and performing inverted culture at 37 deg.C overnight to obtain positive clone, i.e. recombinant genetically engineered bacteria.
The sequencing results are spliced as follows: the single-underlined region is the AlEcR-A gene region. The gray area is a restriction enzyme site;
TGCATCACCGCATGCGTGCTATGCACATCCAATTGTGGAGCGGATACATTGATGTGCTAGCGCATATCCAGTGTAGTAGGCAGTCCTCAGAGTTATCGTTGATACCCCTCGTAGTGCACATTCCTTTAACGCTTCAAAATCTGTAAAGCACGCCATATCGCCGAAAGGCACACTTAATTATTAAGAGGTAATACACC
ATGGGCGAGGAGAAGCGGGCAGACGATGACTGGATGGTGAGCGGTGGCCCCCCCAGAAACTATCAGACCAACGGGG GCTATCCGTCCCCAACTATGTCCAGCAACAGCTACGACCCTTACAGCCCCAACTCTAAACTAGGTCGTGAGGATTT GAGCCCGCCCAACTCGCTAAACGGCTACAGCGCCGATAGCTGTGATGGCTCGAAGAAGAAGAAGGGGACGGCCACC CGGCAGCAAGAAGAGCTCTGCCTCGTTTGCGGAGATCGAGCTTCGGGTTACCATTATAATGCTCTCACGTGCGAGG GCTGTAAGGGGTTCTTTAGACGGAGTATAACGAAAAACGCGGTCTACCAGTGCAAGTACGGGAACAACTGTGAAAT CGACATGTACATGCGGCGGAAATGTCAGGAATGTCGGCTCAAAAAGTGCCTCAGCGTCGGGATGAGGCCTGAATGT GTGGTACCGGAGTACCAATGCGCGGTGAAACGAAAAGAGAAGAAGGCGCAGAAGGAGAAGGACAAGCCTGTGAGCA CGACAACCATCCCCCCTGAGGCAGTCAAACCTGAGCCTGAACCCCACAGGGTCAGTTTCACATCAAGCCTCTTTCA ATCTGTGATTAAAGAGCCAACCAAACTGTTGCCGGAAAGCGGTGCTGAAGTTGCGCTCAAACATTCGCCCCCCTAC GGCATAAAACCGGTGAGCCCTGAGCAGCAGGAACTCATCAACAGGCTCGTCTACTTTCAAAGCGAGTACGAACACC CCTCGGAGGAAGATGTCCGGAGAATTAACTCACCTAACGAAGATGAGGAGCAGATAGACTTTAGGTTTAGGCATAT AACAGAAATCACAATACTCACCGTTCAACTTATCGTAGAGTTCGCGAAGAGGCTGCCGGGTTTCGATAAAATTATT AAAGAAGATCAAATAGCCTTACTAAAGGCGTGTTCAAGCGAAGTGATGATGCTGCGGACAGCGCGGAAGTACGACG CGAGTACGGACTCCATAGTGTTCGCGGACAACCAGCTGTACTCTCGAGAGTCGTACAACCTTGCCGGAATGGGGGA CGTGGTCGATGACATCCTCAAGTTCTGTCGGCACATGTACCGAATGAAGGTTGACAACGCCGAGTACGCCCTCCTT ACCGCCATCGTTATCTTTTCGGAGAGACCGTCCCTCATGGAGAGTTGGAAAGTCGAAAAGATCCAGGAGACCTACC TAGAAGCCCTCAAGTCCTACGTGGACAACCGAACGAAGTCTCGGTCTCCCACACTCTACGCTAAACTTCTTTCTGT CCTCACGGAGCTTCGAACCCTCGGAAACCAAAACTCCGAAATGTGCTTCTCCCTGAAACTTCAGAACAAGAAGCTA CCGCCCTTCCTAGCCGAGATCTGGGACGTCAACTCGTAA TAGGTAATCTCTGCTTAAAAGCACAGAATCTAAGATCCCTGCCATTTGGCGGGGATTTTTTTATTTGTTTTCAGGAAATAAATAATCGATCGCGTAATAAAATCTATTATTATTTTTGTGAAGAATAAATTTGGGTGCAATGAGAATGCGCAGGCCGTTA
second, expression and purification of pCzn1-AlEcR-A recombinant protein
1. IPTG induced expression of pCzn1-AlEcR-A carrier fusion protein
1) The positive monoclonal on the transformation plate was selected and inoculated into a tube containing 50. mu.g/ml ampicillin (Amp) in 3ml of LB medium, and shaken overnight at 37 ℃ and 220 rpm;
2) the following day is as follows: 100 in 50 u g/ml Amp 30ml LB culture solution, 37 degrees C220 rpm shake until bacterial OD600 is 0.6-0.8 (about 2 h);
3) taking out 1ml of culture, centrifuging at 10000g of room temperature for 2min, discarding supernatant, and resuspending the thallus precipitate with 100 μ l of 1 Xloading buffer;
4) adding IPTG into the rest culture in the step 3) until the final concentration is 0.5mM, shaking at 37 ℃ and 220rpm for 4h, and inducing the expression of AlEcR-A His fusion protein;
5) 1ml of the culture obtained after the induction in step 4) was taken out, centrifuged at 12000g at room temperature for 2min, the supernatant was discarded, and the pellet was resuspended in 100. mu.l of 1 Xloading buffer.
6) The 12% SDS-PAGE analysis showed that the target protein was mainly present in the precipitate, and the results are shown in FIG. 3. SDS-PAGE shows that the concentration of the sodium dodecyl sulfate is 0.5 mmol.L-1The IPTG-induced pCzn1-AlEcR-A recombinant plasmid can specifically Express A protein of about 55kD, and the theoretical size is consistent with that, which shows that the AlEcR-A gene is successfully expressed in EscherichiA coli Arctic Express cells, but the IPTG-induced pCzn1-AlEcR-A recombinant plasmid does not have the protein expression of the band. In addition, the recombinant AlEcR-A protein induced to be expressed is mainly distributed in the sediment, and is hardly expressed in the supernatant, which indicates that the AlEcR-A recombinant protein mainly exists in the form of inclusion bodies.
2. Ni-column affinity purification of fusion proteins
1) Centrifuging the culture bacteria liquid subjected to induced expression at low temperature of 6000g for 10min, and carrying out precipitation, heavy suspension and ultrasonic crushing on thalli in a lysine buffer; centrifuging the ultrasonically-broken cell lysate at 4 ℃ and 10000g for 20min, and collecting the precipitate; inclusion bodies were washed 3 times with inclusion body wash (20mM Tris, 1mM EDTA, 2M urea, 1M NaCl, 1% Triton X-100, pH 8.0); the inclusion bodies were dissolved in a dissolution Buffer (20mM Tris, 5mM DTT, 8M urea, pH8.0) in proportion, the above solution was added dropwise to 20mM Tris-HCL and 5mM EDTA Buffer (pH 7.8) Buffer, gradually diluted in stepwise gradients with slow stirring, and the protein solution was put into dialysis bags and dialyzed overnight in PBS (pH7.4) solution.
2) Loading the inclusion body solution to a Ni-IDA-Sepharose CL-6B affinity chromatography column pre-balanced by Ni-IDABinding-Buffer at the flow rate of 0.5ml/min by using a low-pressure chromatography system;
3) flushing with Ni-IDA Binding-Buffer at a flow rate of 0.5ml/min until the effluent OD280 value reaches the baseline;
4) then flushing with Ni-IDA Washing-Buffer (20mM Tris-HCl, 20mM imidazole, 0.15M NaCl, pH8.0) at a flow rate of 1ml/min until the effluent OD280 value reaches the baseline;
5) finally, eluting the target protein by using Ni-IDA Elution-Buffer (20mM Tris-HCl, 250mM imidazole, 0.15M NaCl, pH8.0) at the flow rate of 1ml/min, and collecting the effluent;
6) adding the collected protein solution into a dialysis bag, dialyzing overnight by using PBS (PH7.4), and determining the concentration of the protein to be 1.3mg/mL by using a protein quantitative kit;
7) an appropriate amount of the dialysate was subjected to 12% SDS-PAGE analysis, and the results are shown in FIG. 4. The purification of the pCzn1-AlEcR-A gene recombinant protein after affinity purification by A Ni column was analyzed by SDS-PAGE electrophoresis. After the elution and dialysis of the buffer solution, the purity of the inclusion body containing the pCzn1-AlEcR-A gene recombinant protein is improved to A greater extent, and only an obvious specific band is present near 55kD, and no other band is seen, which indicates that the purified AlEcR-A recombinant protein is obtained. The theoretical molecular weight of the protein is: about 54.95KD (containing HIS-tag), the translated amino acid sequence is as follows:
MNHKVHHHHHHMMGEEKRADDDWMVSGGPPRNYQTNGGYPSPTMSSNSYDPYSPNSKLGREDLSPPNSL NGYSADSCDGSKKKKGTATRQQEELCLVCGDRASGYHYNALTCEGCKGFFRRSITKNAVYQCKYGNNCEIDMYMRRK CQECRLKKCLSVGMRPECVVPEYQCAVKRKEKKAQKEKDKPVSTTTIPPEAVKPEPEPHRVSFTSSLFQSVIKEPTK LLPESGAEVALKHSPPYGIKPVSPEQQELINRLVYFQSEYEHPSEEDVRRINSPNEDEEQIDFRFRHITEITILTVQ LIVEFAKRLPGFDKIIKEDQIALLKACSSEVMMLRTARKYDASTDSIVFADNQLYSRESYNLAGMGDVVDDILKFCR HMYRMKVDNAEYALLTAIVIFSERPSLMESWKVEKIQETYLEALKSYVDNRTKSRSPTLYAKLLSVLTELRTLGNQN SEMCFSLKLQNKKLPPFLAEIWDVNS
preparation of monoclonal antibody
1. Animal immunization
Selecting 5 female BALB/c mice with the age of 6-8 weeks, mixing the purified AlEcR-A protein with Freund's adjuvant in the same volume, injecting 50-100 mu g/mouse subcutaneously in the abdomen and back, emulsifying the recombinant protein AlEcR-A with Freund's incomplete adjuvant every 14 days for 2 times, and boosting the immunity once every 2-3 weeks (dose is doubled). And (3) blood sampling detection after the four-immunization, determining the titer of antiserum against AlEcR-A protein by an indirect ELISA method, performing western blotting detection (screening result is shown in figure 5) by using the antiserum after the four-immunization when the titer is more than 1:10,000 (4-immunization result is shown in table 1), and selecting 1-2 positive mice for cell fusion arrangement when the recombinant protein is positive.
Results of ELISA for serum titers in mice after 4 immunizations: after immunization, the mice all generate high titer antibodies, and the specific results are as follows:
coating antigen: protein AlEcR-A
Coating concentration: 5. mu.g/ml, 100. mu.l/well
Coating buffer solution: phosphate buffer (PBS, pH7.4)
Secondary antibody: goat anti-mouse-HRP, 1/5000
TABLE 1 Indirect Elisa results of mouse antiserum after 4 immunizations
Initial dilution 1:500
The titer, i.e., sample OD/blank OD > -2.1 highest dilution.
2. Cell fusion
1) Myeloma cell preparation
One week prior to fusion, SP2/0 cells were expanded in DMEM medium containing 10% FBS. At the time of confluency, the cells grew out of approximately 6T 25 cell culture flasks, and SP2/0 cells were harvested into 50ml centrifuge tubes at the day of confluency and centrifuged at 1000rpm for 5 min. The supernatant was discarded, and then 20ml of DMEM basal medium was added, and the cells were blown off and counted.
2) Spleen cell preparation
Serum ELISA titers after four immunizations were 1: mice above 10000 were immunized 3 days before fusion and 100 μ g of antigen was intraperitoneally injected. Mice to be fused were euthanized by cervical dislocation on the day of fusion. Soaking in 75% ethanol for 5min, aseptically taking out spleen, and placing spleen into culture dish containing 10ml DMEM basic culture. The spleen was removed from the screen and placed in another dish, transferred to the screen, and ground using a syringe. DMEM was added to the screen and the screen was washed to collect more splenocytes into the dish. The cells were transferred to a 10ml centrifuge tube, and the spleen cells were washed twice with serum-free DMEM, centrifuged at 1000rpm for 5min, and the spleen cells were collected and counted.
3) Cell fusion
And mixing myeloma cells and spleen cells, so that the number ratio of the myeloma cells to the spleen cells is 1: preferably 20. The cells were placed in 50ml centrifuge tubes, diluted with DMEM basal medium, and then centrifuged at 1000rpm for 5 min. The supernatant was discarded. The tubes were shaken to homogenize the cells. 0.8ml of 50% PEG was slowly added for 90 seconds, and then 20-30ml of DMEM medium was added to stop the PEG, and the fused cells were placed in a water bath at 37 ℃ for 10 minutes. 1000rpm for 5min, the supernatant was discarded and HAT DMEM medium (purchased from Wuhan Pronace technologies, Ltd.) was added to the supernatant, and the fused cells were plated in 96-well plates at 100. mu.l per well. The cell culture plate was then placed in CO2Culturing in an incubator. The cloning rate of the hybridoma cells is over 50 percent, a small amount of cell fragments exist, and the cell growth state is good when the hybridoma cells are checked 4 days after fusion. The screening assay was started 10 days after fusion.
3. Fusion screening and subcloning
1) Fusion screening
The day before the assay, 5. mu.g/ml antigen was coated with PBS on ELISA plates overnight. And (3) sucking 100 mu l of cell supernatant per well on the next day, performing ELISA detection, judging positive wells according to an ELISA result (the positive wells are judged if the OD value of the sample wells/the OD value of the negative wells are more than or equal to 2.1), picking the positive wells detected on the whole plate by using a single-channel pipettor, performing secondary confirmation detection, further confirming the positive wells, and performing subcloning on the determined positive well cells.
And fusion screening results: 2# mice with higher titer and positive WB detection are selected for cell fusion, and the results of screening positive clones by ELISA are shown in the following table 2:
coating antigen: protein AlEcR-A
Coating concentration: 5. mu.g/ml, 100. mu.l/well
Coating buffer solution: phosphate buffer (PBS, pH7.4)
Secondary antibody: goat anti-mouse-HRP, 1/5000
Table 2: elisa results of cell supernatants after 2# mice fusion
① size board
② size board
③ size board
④ size board
⑤ size board
2) Subcloning
And (3) blowing cells in the positive holes, counting, adding N/4ml (N refers to the number of the positive cloning holes) of DMEM culture medium into the centrifuge tube, taking 100 mu l of cell suspension into the centrifuge tube, uniformly blowing, then reserving 1ml, supplementing DMEM to 4ml, uniformly blowing, and reserving 100 mu l (about 2 drops) of DMEM at the bottom of the tube. Adding DMEM into a centrifuge tube to 5ml, dropwise adding the DMEM into the first three rows of a 96-well plate after uniformly mixing, keeping 1.8-2ml of DMEM at the bottom of a drop tube of each hole, replenishing DMEM into 5ml, dropwise adding the DMEM into D, E, F three rows of the 96-well plate after uniformly blowing, keeping 1.5-1.8ml of DMEM at the bottom of the tube, replenishing DMEM into 2.8-3ml of DMEM, dropwise adding the DMEM into G, H rows of the 96-well plate after uniformly blowing, keeping a drop in each hole, observing under a microscope after 7-10 days, detecting a hole with clone growth, marking a hole with a monoclonal cell, picking a monoclonal cell which is positive as much as possible to perform subcloning again, and picking out the hole with the monoclonal cell to perform expanded culture for a fixed strain after detecting that the.
Results after subcloning of cell lines: 8 positive cells (with high OD values in Table 2, indicated by grey areas) were selected for subcloning, and 11 positive cells were screened by ELISA and the results are shown in Table 3 below:
coating antigen: protein AlEcR-A
Coating concentration: 5. mu.g/ml, 100. mu.l/well
Coating buffer solution: phosphate buffer (PBS, pH7.4)
Secondary antibody: goat anti-mouse-HRP, 1/5000
Table 3: elisa results of cell supernatants after strain determination:
cell line name
|
OD value (450nm)
|
3D6
|
2.710
|
3G5
|
2.388
|
5D9
|
2.333
|
7D9
|
2.648
|
7G3
|
2.816
|
7G4
|
3.009
|
8B8
|
2.884
|
8D11
|
3.243
|
8H7
|
3.122
|
8H9
|
3.118
|
8G12
|
3.043 |
After A mouse is immunized by using A recombinant protein pCzn1-AlEcR-A expressed by escherichiA coli, after 10d of cell fusion, the positive cloning rate of ELISA detection after antigen coating reaches 100%, and the OD450nm value of hybridomA cell supernatants collected at different periods is almost unchanged. Obtaining 1 monoclonal antibody hybridomA cell strain which can stably secrete anti-AlEcR-A protein and is named as 8H7, wherein the preservation number of the cell strain is CCTCC NO: c2016206, which was deposited in China Center for Type Culture Collection (CCTCC) at 12 months and 1 day of 2016.
The cell line was amplified and cultured to obtain a fixed strain, and the specificity of the antibody was determined.
4. Ascites preparation, agarose affinity medium Protein A purified antibody and antibody identification
1) Preparation of ascites
From table 3 above, this OD was not the highest, 8D11, 3.243, but 8D11 cells of this monoclonal cell did not fuse well, so 8H7 was selected. Finally 8H7 monoclonal cells are selected for ascites preparation, 0.2mL Freund's incomplete adjuvant is injected into the abdominal cavity of the mouse, and a proper amount of the positive hybridoma cells are injected after 7 days, and then ascites is collected.
2) ProteinA purified antibody
The ascites fluid obtained from 8H7 was purified using agarose affinity medium Protein A. Taking Protein A agarose affinity medium, filling a chromatographic column, mixing ascites and PBS uniformly according to a ratio of 1:1, slowly loading the mixture, eluting the mixture by using glycine elution buffer solution after the antibody is combined to obtain the required purified antibody, immediately dialyzing the mixture in the PBS at 4 ℃ overnight, and detecting the purity, the concentration and the titer every other day; wherein, the concentration of the antibody is: 0.5 mg/ml; antibody volume: 10.0 ml. And (3) identifying the purity of the antibody: after purification the antibody was subjected to SDS-PAGE and stained with Coomassie Brilliant blue, see FIG. 6.
3) Identification of antibody
The antiserum indirect ELISA titer detection method specifically comprises the following steps: 1) designing a coating plate according to the experimental requirement, and marking the lath; 2) coating: diluting AlEcR-A protein with PBS coating solution according to 5 μ g/ml, mixing well, adding into lath, each hole 100 μ l, and refrigerating overnight at 4 deg.C; wherein, the coating antigen: an AlEcR-A protein; coating concentration: diluting according to 5 mu g/ml, 100 mu l/well; coating buffer solution: phosphate buffered saline (PBS, pH 7.4); 3) and (3) sealing: after coating, the coating solution was discarded, the plate was washed 3 times, 200. mu.l of blocking solution was added to each well, and the plate was incubated at 37 ℃ for 1 hour. Taking out the enzyme label plate, discarding the internal liquid, and washing the plate for 1 time; 4) primary anti-reaction: diluting the purified antibody by 1/500, 2 times, wherein each well is 100 μ l, and keeping the temperature in a thermostat at 37 ℃ for 1 h; 5) secondary antibody reaction: taking out the enzyme label plate, discarding the internal liquid, washing the plate for 3 times, adding 100 mul of diluted enzyme-labeled secondary antibody and enzyme-labeled secondary antibody into each hole: goat anti-mouse-HRP, 1/5000. A thermostat at 37 ℃ for 1 hour; 6) color development: taking out the enzyme label plate, discarding the inner liquid, washing the plate for 4 times, adding 100 μ l of TMB color development solution into each hole, determining the color development time according to the color depth, generally 37 deg.C, 15 min; 7) termination the reaction was terminated by adding 100. mu.l of 1M HCl solution to each well. The titer of the sample was determined by reading immediately on the microplate reader at 450nm and the dilution corresponding to wells having an OD greater than 2.1 times the OD of the negative control set (see Table 4).
TABLE 4 Indirect Elisa results of antibodies
Initial dilution 1:500
Titer, i.e.the highest dilution at which sample OD/blank OD > is 2.1
4) Western-blot detection of specificity of monoclonal antibody
The Western-blot assay was performed according to the method of Song et al (2012) with minor routine modifications. And carrying out SDS-PAGE analysis on the prokaryotic expression AlEcR-A recombinant protein and the freshly hatched 3-year nymph of lygus lucorum. And sealing after transferring A PVDF membrane, wherein the primary antibody is the AlEcR-A recombinant protein monoclonal antibody, the secondary antibody is goat anti-mouse HRP marked by horseradish peroxidase, and ECL (electron cyclotron resonance) color development is performed.
Referring to fig. 5, the prepared AlEcR-A recombinant protein monoclonal antibody can be specifically combined with the total green plant bug protein and the recombinant protein, and has no cross reaction with other proteins.
Application example
The prepared AlEcR-A recombinant protein monoclonal antibody is used for analyzing the influence of ecdysone (20E) on the expression level of AlEcR-A protein. With the extension of the 20E treatment time, the expression level of the AlEcR-A protein of the lygus lucorum shows A gradually rising trend. In addition, compared with the distilled water treatment group (CK), the 20E-treated lygus lucorum AlEcR-A protein expression level has certain enrichment effect. See fig. 6.
The above description is only of the preferred embodiments of the present invention, and it should be noted that: it will be apparent to those skilled in the art that various modifications and adaptations can be made without departing from the principles of the invention and these are intended to be within the scope of the invention.
SEQUENCE LISTING
<110> agricultural science and academy of Jiangsu province
<120> monoclonal antibody of ecdysone receptor protein of lygus lucorum and application thereof
<130>SG20161214001
<160>2
<170>PatentIn version 3.3
<210>1
<211>1407
<212>DNA
<213> AlEcR-A Gene
<220>
<221>CDS
<222>(1)..(1407)
<400>1
atg ggc gag gag aag cgg gca gac gat gac tgg atg gtg agc ggt ggc 48
Met Gly Glu Glu Lys Arg Ala Asp Asp Asp Trp Met Val Ser Gly Gly
1 5 10 15
ccc ccc aga aac tat cag acc aac ggg ggc tat ccg tcc cca act atg 96
Pro Pro Arg Asn Tyr Gln Thr Asn Gly Gly Tyr Pro Ser Pro Thr Met
20 25 30
tcc agc aac agc tac gac cct tac agc ccc aac tct aaa cta ggt cgt 144
Ser Ser Asn Ser Tyr Asp Pro Tyr Ser Pro Asn Ser Lys Leu Gly Arg
35 40 45
gag gat ttg agc ccg ccc aac tcg cta aac ggc tac agc gcc gat agc 192
Glu Asp Leu Ser Pro Pro Asn Ser Leu Asn Gly Tyr Ser Ala Asp Ser
50 5560
tgt gat ggc tcg aag aag aag aag ggg acg gcc acc cgg cag caa gaa 240
Cys Asp Gly Ser Lys Lys Lys Lys Gly Thr Ala Thr Arg Gln Gln Glu
65 70 75 80
gag ctc tgc ctc gtt tgc gga gat cga gct tcg ggt tac cat tat aat 288
Glu Leu Cys Leu Val Cys Gly Asp Arg Ala Ser Gly Tyr His Tyr Asn
85 90 95
gct ctc acg tgc gag ggc tgt aag ggg ttc ttt aga cgg agt ata acg 336
Ala Leu Thr Cys Glu Gly Cys Lys Gly Phe Phe Arg Arg Ser Ile Thr
100 105 110
aaa aac gcg gtc tac cag tgc aag tac ggg aac aac tgt gaa atc gac 384
Lys Asn Ala Val Tyr Gln Cys Lys Tyr Gly Asn Asn Cys Glu Ile Asp
115 120 125
atg tac atg cgg cgg aaa tgt cag gaa tgt cgg ctc aaa aag tgc ctc 432
Met Tyr Met Arg Arg Lys Cys Gln Glu Cys Arg Leu Lys Lys Cys Leu
130 135 140
agc gtc ggg atg agg cct gaa tgt gtg gta ccg gag tac caa tgc gcg 480
Ser Val Gly Met Arg Pro Glu Cys Val Val Pro Glu Tyr Gln Cys Ala
145 150 155 160
gtg aaa cga aaa gag aag aag gcg cag aag gag aag gac aag cct gtg 528
Val Lys Arg Lys Glu Lys Lys Ala Gln Lys Glu Lys Asp Lys Pro Val
165 170 175
agc acg aca acc atc ccc cct gag gca gtc aaa cct gag cct gaa ccc 576
Ser Thr Thr Thr Ile Pro Pro Glu Ala Val Lys Pro Glu Pro Glu Pro
180 185 190
cac agg gtc agt ttc aca tca agc ctc ttt caa tct gtg att aaa gag 624
His Arg Val Ser Phe Thr Ser Ser Leu Phe Gln Ser Val Ile Lys Glu
195 200 205
cca acc aaa ctg ttg ccg gaa agc ggt gct gaa gtt gcg ctc aaa cat 672
Pro Thr Lys Leu Leu Pro Glu Ser Gly Ala Glu Val Ala Leu Lys His
210 215 220
tcg ccc ccc tac ggc ata aaa ccg gtg agc cct gag cag cag gaa ctc 720
Ser Pro Pro Tyr Gly Ile Lys Pro Val Ser Pro Glu Gln Gln Glu Leu
225 230 235 240
atc aac agg ctc gtc tac ttt caa agc gag tac gaa cac ccc tcg gag 768
Ile Asn Arg Leu Val Tyr Phe Gln Ser Glu Tyr Glu His Pro Ser Glu
245 250 255
gaa gat gtc cgg aga att aac tca cct aac gaa gat gag gag cag ata 816
Glu Asp Val Arg Arg Ile Asn Ser Pro Asn Glu Asp Glu Glu Gln Ile
260 265 270
gac ttt agg ttt agg cat ata aca gaa atc aca ata ctc acc gtt caa 864
Asp Phe Arg Phe Arg His Ile Thr Glu Ile Thr Ile Leu Thr Val Gln
275 280 285
ctt atc gta gag ttc gcg aag agg ctg ccg ggt ttc gat aaa att att 912
Leu Ile Val Glu Phe Ala Lys Arg Leu Pro Gly Phe Asp Lys Ile Ile
290 295 300
aaa gaa gat caa ata gcc tta cta aag gcg tgt tca agc gaa gtg atg 960
Lys Glu Asp Gln Ile Ala Leu Leu Lys Ala Cys Ser Ser Glu Val Met
305 310 315 320
atg ctg cgg aca gcg cgg aag tac gac gcg agt acg gac tcc ata gtg 1008
Met Leu Arg Thr Ala Arg Lys Tyr Asp Ala Ser Thr Asp Ser Ile Val
325 330 335
ttc gcg gac aac cag ctg tac tct cga gag tcg tac aac ctt gcc gga 1056
Phe Ala Asp Asn Gln Leu Tyr Ser Arg Glu Ser Tyr Asn Leu Ala Gly
340 345 350
atg ggg gac gtg gtc gat gac atc ctc aag ttc tgt cgg cac atg tac 1104
Met Gly Asp Val Val Asp Asp Ile Leu Lys Phe Cys Arg His Met Tyr
355 360 365
cga atg aag gtt gac aac gcc gag tac gcc ctc ctt acc gcc atc gtt 1152
Arg Met Lys Val Asp Asn Ala Glu Tyr Ala Leu Leu Thr Ala Ile Val
370 375 380
atc ttt tcg gag aga ccg tcc ctc atg gag agt tgg aaa gtc gaa aag 1200
Ile Phe Ser Glu Arg Pro Ser Leu Met Glu Ser Trp Lys Val Glu Lys
385 390 395 400
atc cag gag acc tac cta gaa gcc ctc aag tcc tac gtg gac aac cga 1248
Ile Gln Glu Thr Tyr Leu Glu Ala Leu Lys Ser Tyr Val Asp Asn Arg
405 410 415
acg aag tct cgg tct ccc aca ctc tac gct aaa ctt ctt tct gtc ctc 1296
Thr Lys Ser Arg Ser Pro Thr Leu Tyr Ala Lys Leu Leu Ser Val Leu
420 425 430
acg gag ctt cga acc ctc gga aac caa aac tcc gaa atg tgc ttc tcc 1344
Thr Glu Leu Arg Thr Leu Gly Asn Gln Asn Ser Glu Met Cys Phe Ser
435 440 445
ctg aaa ctt cag aac aag aag cta ccg ccc ttc cta gcc gag atc tgg 1392
Leu Lys Leu Gln Asn Lys Lys Leu Pro Pro Phe Leu Ala Glu Ile Trp
450 455 460
gac gtc aac tcg taa 1407
Asp Val Asn Ser
465
<210>2
<211>468
<212>PRT
<213> AlEcR-A protein
<400>2
Met Gly Glu Glu Lys Arg Ala Asp Asp Asp Trp Met Val Ser Gly Gly
1 5 10 15
Pro Pro Arg Asn Tyr Gln Thr Asn Gly Gly Tyr Pro Ser Pro Thr Met
20 25 30
Ser Ser Asn Ser Tyr Asp Pro Tyr Ser Pro Asn Ser Lys Leu Gly Arg
35 40 45
Glu Asp Leu Ser Pro Pro Asn Ser Leu Asn Gly Tyr Ser Ala Asp Ser
50 55 60
Cys Asp Gly Ser Lys Lys Lys Lys Gly Thr Ala Thr Arg Gln Gln Glu
65 70 75 80
Glu Leu Cys Leu Val Cys Gly Asp Arg Ala Ser Gly Tyr His Tyr Asn
85 90 95
Ala Leu Thr Cys Glu Gly Cys Lys Gly Phe Phe Arg Arg Ser Ile Thr
100 105 110
Lys Asn Ala Val Tyr Gln Cys Lys Tyr Gly Asn Asn Cys Glu Ile Asp
115 120 125
Met Tyr Met Arg Arg Lys Cys Gln Glu Cys Arg Leu Lys Lys Cys Leu
130 135 140
Ser Val Gly Met Arg Pro Glu Cys Val Val Pro Glu Tyr Gln Cys Ala
145 150 155 160
Val Lys Arg Lys Glu Lys Lys Ala Gln Lys Glu Lys Asp Lys Pro Val
165 170 175
Ser Thr Thr Thr Ile Pro Pro Glu Ala Val Lys Pro Glu Pro Glu Pro
180 185 190
His Arg Val Ser Phe Thr Ser Ser Leu Phe Gln Ser Val Ile Lys Glu
195 200 205
Pro Thr Lys Leu Leu Pro Glu Ser Gly Ala Glu Val Ala Leu Lys His
210 215 220
Ser Pro Pro Tyr Gly Ile Lys Pro Val Ser Pro Glu Gln Gln Glu Leu
225 230 235 240
Ile Asn Arg Leu Val Tyr Phe Gln Ser Glu Tyr Glu His Pro Ser Glu
245 250 255
Glu Asp Val Arg Arg Ile Asn Ser Pro Asn Glu Asp Glu Glu Gln Ile
260 265 270
Asp Phe Arg Phe Arg His Ile Thr Glu Ile Thr Ile Leu Thr Val Gln
275 280 285
Leu Ile Val Glu Phe Ala Lys Arg Leu Pro Gly Phe Asp Lys Ile Ile
290 295 300
Lys GluAsp Gln Ile Ala Leu Leu Lys Ala Cys Ser Ser Glu Val Met
305 310 315 320
Met Leu Arg Thr Ala Arg Lys Tyr Asp Ala Ser Thr Asp Ser Ile Val
325 330 335
Phe Ala Asp Asn Gln Leu Tyr Ser Arg Glu Ser Tyr Asn Leu Ala Gly
340 345 350
Met Gly Asp Val Val Asp Asp Ile Leu Lys Phe Cys Arg His Met Tyr
355 360 365
Arg Met Lys Val Asp Asn Ala Glu Tyr Ala Leu Leu Thr Ala Ile Val
370 375 380
Ile Phe Ser Glu Arg Pro Ser Leu Met Glu Ser Trp Lys Val Glu Lys
385 390 395 400
Ile Gln Glu Thr Tyr Leu Glu Ala Leu Lys Ser Tyr Val Asp Asn Arg
405 410 415
Thr Lys Ser Arg Ser Pro Thr Leu Tyr Ala Lys Leu Leu Ser Val Leu
420 425 430
Thr Glu Leu Arg Thr Leu Gly Asn Gln Asn Ser Glu Met Cys Phe Ser
435 440 445
Leu Lys Leu Gln Asn Lys Lys Leu Pro Pro Phe Leu Ala Glu Ile Trp
450 455 460
Asp Val Asn Ser
465